The Impact of Antibiotic Use on the Efficacy of Immune Checkpoint Inhibitors in Cancer Treatment: A Meta-Analysis

Cancer is a major health concern, affecting millions of people worldwide. Newer therapies like immunotherapy are being used to treat some cancers, these work by helping the body's immune system to recognize and attack cancer cells. One type of immunotherapy is Immune Checkpoint Inhibitors (ICIs). While ICIs have improved outcomes for many cancer patients, not all patients respond well to this treatment. Researchers are working to understand what factors might influence how well ICIs work. Checkpoint inhibitors are a type of immunotherapy drug that enhances the immune system's ability to recognize and attack cancer cells. They work by blocking "checkpoint" proteins, which are naturally present in the immune system to prevent it from attacking the body's own cells, but are "mimicked" on cancer cells. By blocking these checkpoints, checkpoint inhibitors allow T cells (a type of immune cell) to target and destroy cancer cells more effectively.

One factor that might affect ICI treatment is the use of antibiotics. Antibiotics are medications used to treat bacterial infections, but they also impact the gut microbiome—the community of bacteria and other microorganisms living in our intestines. Recent studies suggest that the gut microbiome plays an important role in how the immune system works, including its ability to fight cancer. Since antibiotics can change the gut microbiome, they might also affect how well ICIs work in cancer treatment.

This study aims to find out whether using antibiotics during ICI treatment affects cancer treatment outcomes. Specifically, we want to see if cancer patients who take antibiotics have different results compared to those who do not take antibiotics during ICI therapy. This research could help doctors make better decisions about using antibiotics in cancer patients receiving immunotherapy, potentially leading to improved treatment outcomes.
This study will use clinical trial data from cancer patients who received ICI treatment. We will compare the health outcomes of patients who used antibiotics during their treatment with those who did not.

By analyzing this data, we hope to answer important questions:
• Does taking antibiotics during ICI treatment affect cancer treatment outcomes?
• Are certain types of antibiotics more likely to impact treatment results?
• Does the timing or duration of antibiotic use matter?

If our study finds that antibiotics negatively impact ICI treatment, it could lead to new guidelines on when and how to use antibiotics in cancer patients. This could improve the effectiveness of cancer treatment, leading to better outcomes for patients.